Silex Systems Limited is an Australian technology commercialization company specializing in the development and licensing of SILEX laser-based isotope separation technology. The company’s core products and services include laser enrichment technology applications across three main segments: uranium production and enrichment for nuclear power; silicon enrichment for quantum computing; and medical isotope enrichment for novel cancer therapies. Silex operates through segments including Silex Systems, Translucent, and Silex USA, with geographic operations primarily in Australia, the United States, and the United Kingdom. Founded in 1987 and headquartered in Sydney, Australia, Silex holds a 51% ownership stake in Global Laser Enrichment LLC (GLE), a joint venture with Cameco Corporation that exclusively licenses the SILEX uranium enrichment technology. Recent major developments include the acquisition of GE Hitachi’s interest in GLE, enabling Silex to lead commercialisation efforts for uranium enrichment in the US, including the Paducah Laser Enrichment Facility project. In 2024-2025, Silex commenced its Q-Si (quantum silicon) production project aimed at developing production modules for silicon enrichment, advancing applications in quantum computing. The company also secured approximately AU$130 million in institutional funding in 2025 to support technology scale-up and commercialisation activities. GLE achieved Technology Readiness Level 6 (TRL-6) for its laser uranium enrichment pilot demonstration facility, with full-scale testing imminent. Strategic collaborations with US government initiatives and industry partners underpin Silex’s expansion and diversification in nuclear fuel and advanced material enrichment markets.